Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

94.96 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

74 75 Next >

Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst ↗

March 06, 2025

Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.

Via Benzinga

Inside The Quantum Computing Crash Triggered By Nvidia CEO — And What His Upcoming 'Quantum Day' May Bring ↗

March 06, 2025

Nvidia's CEO threw cold water on quantum computing by scoffing at its near-term utility. Quantum execs are sharpening their arguments.

Via Investor's Business Daily

Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials ↗

March 06, 2025

Via Benzinga

Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis ↗

March 03, 2025

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Via Benzinga

Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps

March 01, 2025

From AstraZeneca

Via Business Wire

What's a Good Price for AstraZeneca Stock? ↗

February 19, 2025

Via The Motley Fool

IonQ CEO Fires Back At Nvidia's Jensen Huang: 'We Remain The 800 Pound Guerrilla' ↗

February 28, 2025

IonQ CEO Niccolo De Masi is confident that quantum computing will soon be the third leg of computing. With major partnerships and predicted GAAP revenue, IonQ is poised to be a leader in the industry.

Via Benzinga

Snowflake Expands Microsoft, OpenAI Partnership: Will Include Other Prominent Models Like Anthropic's Claude, Meta's Llama, And DeepSeek ↗

February 27, 2025

Snowflake unveiled its deeper partnership with Microsoft Corp during its earnings call and introduced its new AI agent Cortex.

Via Benzinga

Topics Artificial Intelligence Earnings

AstraZeneca's Investigational Cancer Drug Shows First-Line Benefit In Combination With Widely Cancer Medicines ↗

February 26, 2025

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

Via Benzinga

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

February 26, 2025

From AstraZeneca

Via Business Wire

How Is The Market Feeling About AstraZeneca? ↗

February 17, 2025

Via Benzinga

Is NASDAQ:AZN suited for quality investing? ↗

February 14, 2025

A fundamental analysis of (NASDAQ:AZN): Is ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) a Strong Candidate for Quality Investing?

Via Chartmill

Ranked: 10 Largest Companies In The U.S., Europe, And China ↗

February 25, 2025

The top nine American companies by market cap are all worth more than a trillion dollars.

Via Talk Markets

Topics Stocks / Equities

Synchronicity: Denying The Unexplainable ↗

February 24, 2025

Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?

Via Talk Markets

Topics Stocks / Equities

3 Magnificent Growth Stocks to Buy Right Now ↗

February 22, 2025

Via The Motley Fool

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

February 21, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million ↗

February 20, 2025

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent.

Via Benzinga

AZN Deadline: Rosen Law Firm Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm – AZN

February 19, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Big Money Is Betting On Europe, Should You? 3 ETFs To Watch ↗

February 19, 2025

European fund managers are bullish on stocks, with 3 top ETFs to consider: SPDR EURO STOXX 50 (FEZ), Vanguard FTSE Europe (VGK), Xtrackers MSCI EAFE Hedged Equity (DBEF)

Via Benzinga

Topics ETFs

George Soros Makes Fresh Bets On Alphabet, Small Caps: What About SPY Puts And Alibaba? ↗

February 19, 2025

Soros Fund Management made bullish bets on Alphabet and small-cap stocks while reducing exposure to SPY and Chinese tech in Q4.

Via Benzinga

Deadline Soon: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

February 19, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

February 19, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

February 18, 2025

Via Benzinga

2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025 ↗

February 15, 2025

Via The Motley Fool

AstraZeneca's Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients ↗

February 14, 2025

AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority Review expected in Q2 2025.

Via Benzinga

IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial

February 14, 2025

From AstraZeneca

Via Business Wire

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗

February 13, 2025

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.

Via Benzinga

This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

February 13, 2025

Via Benzinga

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

February 12, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Trade Desk, Leidos, Devon Energy And A Major Health Care Stock On CNBC's 'Final Trades' ↗

February 12, 2025

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.